$555.51
-21.47-3.72%
In chiusura: -
$557.03
1.520.27%
After hour: 7:56 PM EDT
Regeneron Pharmaceuticals segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di Regeneron Pharmaceuticals utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
REGN | Regeneron Pharmaceuticals | $12.46 | $8.98 | — | — | $3.72B | $3.58B | — | — | 10/30/2025 | |
REGN | Regeneron Pharmaceuticals | $11.56 | $7.55 | $12.89 | 70.73% | $3.55B | $3.31B | $3.68B | 11.34% | 08/01/2025 | |
REGN | Regeneron Pharmaceuticals | $9.55 | $8.82 | $8.22 | -6.80% | $3.15B | $3.29B | $3.03B | -7.93% | 04/29/2025 | |
REGN | Regeneron Pharmaceuticals | $11.86 | $11.19 | $12.07 | 7.86% | $3.43B | $3.75B | $3.79B | 1.04% | 02/04/2025 | |
REGN | Regeneron Pharmaceuticals | $11.59 | $11.69 | $12.46 | 6.59% | $3.36B | $3.67B | $3.72B | 1.39% | 10/31/2024 | |
REGN | Regeneron Pharmaceuticals | $10.24 | $10.53 | $11.56 | 9.78% | $3.16B | $3.36B | $3.55B | 5.57% | 08/01/2024 | |
REGN | Regeneron Pharmaceuticals | $10.09 | $10.10 | $9.55 | -5.45% | $3.16B | $3.22B | $3.15B | -2.33% | 05/02/2024 | |
REGN | Regeneron Pharmaceuticals | $12.56 | $10.77 | $11.86 | 10.12% | $3.41B | $3.29B | $3.43B | 4.38% | 02/02/2024 | |
REGN | Regeneron Pharmaceuticals | $11.14 | $10.77 | $11.59 | 7.61% | $2.94B | $3.22B | $3.36B | 4.44% | 11/02/2023 | |
REGN | Regeneron Pharmaceuticals | $9.77 | $9.92 | $10.24 | 3.23% | $2.86B | $3.01B | $3.16B | 4.92% | 08/03/2023 | |
REGN | Regeneron Pharmaceuticals | $11.49 | $9.60 | $10.09 | 5.10% | $2.96B | $3.00B | $3.16B | 5.40% | 05/04/2023 | |
REGN | Regeneron Pharmaceuticals | $23.42 | $10.03 | $12.56 | 25.22% | $4.95B | $3.13B | $3.41B | 9.07% | 02/03/2023 | |
REGN | Regeneron Pharmaceuticals | $15.37 | $9.52 | $11.14 | 17.02% | $3.45B | $2.88B | $2.94B | 1.94% | 11/03/2022 | |
REGN | Regeneron Pharmaceuticals | $25.80 | $9.54 | $9.77 | 2.41% | $5.14B | $2.79B | $2.86B | 2.40% | 08/03/2022 | |
REGN | Regeneron Pharmaceuticals | $9.89 | $10.04 | $11.49 | 14.44% | $2.53B | $2.73B | $2.96B | 8.61% | 05/04/2022 | |
REGN | Regeneron Pharmaceuticals | $9.53 | $18.11 | $23.72 | 30.98% | $2.42B | $4.47B | $4.95B | 10.78% | 02/04/2022 | |
REGN | Regeneron Pharmaceuticals | $8.36 | $9.49 | $15.37 | 61.96% | $2.29B | $2.79B | $3.45B | 23.76% | 11/04/2021 | |
REGN | Regeneron Pharmaceuticals | $7.16 | $17.69 | $25.80 | 45.85% | $1.95B | $3.89B | $5.14B | 32.11% | 08/05/2021 | |
REGN | Regeneron Pharmaceuticals | $6.60 | $9.03 | $9.89 | 9.52% | $1.83B | $2.56B | $2.53B | -1.21% | 05/06/2021 | |
REGN | Regeneron Pharmaceuticals | $7.50 | $8.39 | $9.53 | 13.59% | $2.17B | $2.42B | $2.42B | 0.12% | 02/05/2021 | |
REGN | Regeneron Pharmaceuticals | $6.67 | $7.09 | $8.36 | 17.91% | $2.05B | $2.09B | $2.29B | 9.76% | 11/05/2020 |
Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-01 | $12.89 | $7.55 | 70.7 % |
Q1 | 2025-04-29 | $8.22 | $8.82 | -6.80 % |
Q4 | 2025-02-04 | $12.07 | $11.19 | 7.86 % |
Q3 | 2024-10-31 | $12.46 | $11.69 | 6.59 % |
Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
---|---|---|---|---|
Q2 | 2025-08-01 | $3.68B | $3.31B | 11.3 % |
Q1 | 2025-04-29 | $3.03B | $3.29B | -7.93 % |
Q4 | 2025-02-04 | $3.79B | $3.75B | 1.04 % |
Q3 | 2024-10-31 | $3.72B | $3.67B | 1.39 % |
Si prevede che Regeneron Pharmaceuticals (REGN) fornisca risultati il ottobre 30, 2025. Gli ultimi risultati sono stati pubblicati il agosto 1, 2025 per il Q2.
L'EPS effettivo era $12.89, che superato la stima di $7.55.
Le entrate effettive sono state $3.7B, che superato la stima di $3.3B.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.